These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H; Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465 [TBL] [Abstract][Full Text] [Related]
12. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508 [TBL] [Abstract][Full Text] [Related]
13. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238 [TBL] [Abstract][Full Text] [Related]
14. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M; Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973 [TBL] [Abstract][Full Text] [Related]
15. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ; Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324 [TBL] [Abstract][Full Text] [Related]
17. MVA85A vaccine to enhance BCG for preventing tuberculosis. Kashangura R; Jullien S; Garner P; Johnson S Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012915. PubMed ID: 31038197 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038 [TBL] [Abstract][Full Text] [Related]